Skip to main content

CEFOXITIN DEMOGEN (Demogen Australia Pty Ltd trading as DEMOGEN Pharmaceuticals)

Product name
CEFOXITIN DEMOGEN
Date registered
Evaluation commenced
Decision date
Approval time
125 (255 working days)
Active ingredients
Cefoxitin sodium
Registration type
New generic medicine
Indication

Cefoxitin (as sodium) Powder for Injection is indicated for the treatment of the following infections when due to susceptible organisms (see section 5.1 Pharmacodynamic properties - Microbiology) peritonitis and other intra-abdominal and intra- pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections.

Cefoxitin (as sodium) Powder for Injection has a high degree of stability against beta- lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. It can also be used in mixed infections provided that the organisms are sensitive to it.

Cefoxitin (as sodium) Powder for Injection can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

Cefoxitin (as sodium) Powder for Injection is also indicated for the prevention of post operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.